Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Aurinia Pharmaceuticals Inc banner

Aurinia Pharmaceuticals Inc
NASDAQ:AUPH

Watchlist Manager
Aurinia Pharmaceuticals Inc Logo
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Watchlist
Price: 15.35 USD 0.72% Market Closed
Market Cap: $2B
Write Note Create Alert Ask AI

Wall St Price Targets

AUPH Price Targets Summary
Aurinia Pharmaceuticals Inc

Wall Street analysts forecast AUPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AUPH is 17.34 USD with a low forecast of 15.15 USD and a high forecast of 22.05 USD.

AUPH Lowest Forecast
Wall Street Target
$15.15
-1% Downside
AUPH Average Forecast
Wall Street Target
$17.34
13% Upside
AUPH Highest Forecast
Wall Street Target
$22.05
44% Upside
Lowest Forecast
Price Target
15.15 USD
1% Downside
Average Forecast
Price Target
17.34 USD
13% Upside
Highest Forecast
Price Target
22.05 USD
44% Upside
Aurinia Pharmaceuticals Inc Competitors:
Price Targets
CFFN
Capitol Federal Financial Inc
-3% Downside
AMAL
Amalgamated Bank
-1% Downside
CFFN
Capitol Federal Financial Inc
-3% Downside
AMAL
Amalgamated Bank
-1% Downside

Revenue
Forecast

34% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
34% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 34%. The projected CAGR for the next 8 years is 16%.

What are analyst estimates?

Gross Profit
Forecast

33% / Year
Past Growth
22% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
33% / Year
Past Growth
22% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 33%. The projected CAGR for the next 3 years is 22%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
24% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
N/A
Past Growth
24% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

The compound annual growth rate for Operating Income over the next 8 years is 24%.

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
33% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
33% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

The compound annual growth rate for Pre-Tax Income over the next 3 years is 33%.

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat
N/A
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat

The compound annual growth rate for Net Income over the next 8 years is 6%.

What are analyst estimates?

Continue AUPH Research

Summary
AUPH intrinsic value, competitors valuation, and company profile.
DCF Valuation
AUPH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AUPH stock valuation using valuation multiples.
Wall St Estimates
AUPH price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AUPH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Aurinia Pharmaceuticals Inc listings:
F • EUR
IKAP
 SWB • EUR
IKAP
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is AUPH's stock price target?
Price Target
17.34 USD

According to Wall Street analysts, the average 1-year price target for AUPH is 17.34 USD with a low forecast of 15.15 USD and a high forecast of 22.05 USD.

What is the Revenue forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
16%

Over the last 13 years, the compound annual growth rate for Revenue has been 34%. The projected CAGR for the next 8 years is 16%.

What is the Gross Profit forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
22%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 33%. The projected CAGR for the next 3 years is 22%.

What is the Operating Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
24%

The compound annual growth rate for Operating Income over the next 8 years is 24%.

What is the Pre-Tax Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
33%

The compound annual growth rate for Pre-Tax Income over the next 3 years is 33%.

What is the Net Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
6%

The compound annual growth rate for Net Income over the next 8 years is 6%.

Back to Top
ALPHA SPREAD
Follow us
Join 349,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett